Allogene Therapeutics Enters Termination Agreement With Overland Therapeutics On May 12, 2026; Terminates Exclusive License Agreement With Overland Therapeutics Effective May 12, 2026; No Termination Payments Made In Connection With Termination Agreement; To Hold About 3% Of Overland Equity After Surrendering Portion For No Consideration